Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
The post-β-lactamase-inhibitor effect (PBLIE) of tazobactam combined with ceftolozane was evaluated by time-kill assays on two clinical Escherichia coli strains producing CTX-M-15 with or without TEM-1. The organisms were exposed (2 h) to 4 μg/ml/4 μg/ml of ceftolozane-tazobactam (4× MIC), 4 μg/ml of ceftolozane, and medium containing no drug, washed, and resuspended in medium alone or medium containing ceftolozane-tazobactam or ceftolozane. The PBLIE was determined as 1.3 to 2.1 h, and a postantibiotic effect was measured as 0.8 to 0.9 h.
JMI Laboratories, North Liberty, Iowa, USA.
Helio S
HS
Sader
Paul R
PR
Rhomberg
Ronald N
RN
Jones
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology*; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078142:Tazobactam; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C519491:ceftolozane; D010397:Penicillanic Acid; D001618:beta-Lactamases; D000078142:Tazobactam